We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
2.Wang, SJ, Sihra, TS, Gea, PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuropharmacol Neurotoxicol. 2001; 12(10): 2255–2258.Google ScholarPubMed
3
3.Anand, A, Charney, DS, Oren, D, et al. Attenuation of neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry. 2000; 57: 270–276.CrossRefGoogle ScholarPubMed
4
4.Sierra, M, Phillips, M, Ivin, G, et al. A placebo-controlled, cross-over trial of Lamotrigine in depersonalization disorder. J Psychopharmacol. 2003; 17(1): 103–105.CrossRefGoogle ScholarPubMed
5
5.Medford, N, Sierra, M, Baker, D, David, A. Understanding and treating depersonalization disorder. Advances in Psychiatric Treatment. 2005; 11: 92–100.CrossRefGoogle Scholar
6
6.Sarkar, J, Jones, N, Sullivan, G. A case of depersonalization-derealization syndrome during treatment with Quetiapine. J Psychopharmacol.2001; 15(3): 209–211.CrossRefGoogle ScholarPubMed
7
7.Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.1981; 30: 239–245.CrossRefGoogle ScholarPubMed